Abstract
The current status of DT targets for cancer therapy is reviewed with regard to beam composition and energy as well as target configuration, lifetime, and neutron output. The advantages and shortcomings of the various target designs are discussed. It is concluded that several approaches can provide the necessary dose rate and target lifetime for clinical therapy purposes.